The next evolution in this drug class involves inhibitors that only target mutated PI3K. This specificity aims to avoid effects on wild-type PI3K, which is involved in insulin signaling. The goal is to dramatically reduce severe side effects like hyperglycemia, which could allow for higher, more effective drug doses.
Despite superior efficacy and a manageable side effect profile, Gedatolisib's requirement for weekly IV infusions is its primary drawback. If it were an oral drug, it would be universally adopted for post-CDK4/6 inhibitor breast cancer treatment, as its clinical benefits are otherwise compelling.
Although 22% of patients experienced severe (Grade 3) mucositis, the treatment discontinuation rate due to adverse events was only about 3%. This disparity highlights that the side effect, while serious, was effectively managed with proactive dose reductions, preventing it from being a treatment-limiting factor for most patients.
While initially approved for PIK3CA wild-type patients, Gedatolisib also doubled progression-free survival in patients with PIK3CA mutations compared to the standard of care. This mutation-agnostic benefit simplifies treatment decisions for clinicians, broadens the drug's applicability, and removes the need for mutation-specific testing to determine eligibility.